Literature DB >> 8656424

Selection of RNAs that bind to duplex DNA at neutral pH.

G A Soukup1, A D Ellington, L J Maher.   

Abstract

RNA that are capable of binding duplex DNA in a site-specific manner have potential applications in gene therapy strategies. Such RNAs might be targeted to DNA sequences in a gene promoter and prevent initiation of transcription by occluding transcription factors and/or RNA polymerases. RNA oligonucleotides that bind homopurine/homopyrimidine DNA sequences by forming triple-helical complexes involving T.A.T and C+.G.C base-triplets can be rationally designed. However, the formation of such pyrimidine motif triple helices typically requires mildly acidic conditions. In addition, the proper oligonucleotide sequence must be optimally presented within a longer RNA transcript if it is to be synthesized in vivo. To address these issues, RNAs were selected from pools of random sequences for binding to a homopurine/homopyrimidine DNA sequence. RNAs selected for binding the duplex DNA target between pH 6.5 and pH 7.4 were characterized by sequence analysis and binding studies. All RNAs isolated by selection and amplification were found to contain a pyrimidine recognition sequence for binding the duplex DNA target via conventional triple helix formation. The selected approximately 85 nt RNAs have dissociation constants that approach, but do not surpass, the binding affinity of a 21 nt RNA oligonucleotide that binds the DNA target sequence by forming a canonical triple helix. The presence of a pyrimidine recognition sequence within a longer RNA transcript is not sufficient for high affinity. Experimental data and secondary structure predictions suggest that the context of the pyrimidine recognition sequence within selected RNAs is a very important determinant of DNA binding affinity. These studies provide insight into the development of RNA transcripts that may function as gene-specific repressors by forming triple helices with DNA in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656424     DOI: 10.1006/jmbi.1996.0314

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  Streptavidin aptamers: affinity tags for the study of RNAs and ribonucleoproteins.

Authors:  C Srisawat; D R Engelke
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

Review 2.  A model for RNA-mediated gene silencing in higher plants.

Authors:  M Wassenegger; T Pélissier
Journal:  Plant Mol Biol       Date:  1998-05       Impact factor: 4.076

3.  Selection and characterization of RNAs that relieve transcriptional interference in Escherichia coli.

Authors:  G A Soukup; J J Maher
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

4.  Selection and characterization of anti-NF-kappaB p65 RNA aptamers.

Authors:  Susan E Wurster; L James Maher
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

5.  Creation of RNA molecules that recognize the oxidative lesion 7,8-dihydro-8-hydroxy-2'-deoxyguanosine (8-oxodG) in DNA.

Authors:  S M Rink; J C Shen; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

6.  Selection of RNA aptamers that bind HIV-1 LTR DNA duplexes: strand invaders.

Authors:  Chatchawan Srisawat; David R Engelke
Journal:  Nucleic Acids Res       Date:  2010-08-06       Impact factor: 16.971

Review 7.  Aptamers for DNA Damage and Repair.

Authors:  Maureen McKeague
Journal:  Int J Mol Sci       Date:  2017-10-22       Impact factor: 5.923

8.  Single molecule identification of homology-dependent interactions between long ssRNA and dsDNA.

Authors:  Chenli Liu; Claudia Danilowicz; Nancy Kleckner; Mara Prentiss
Journal:  Nucleic Acids Res       Date:  2016-08-31       Impact factor: 16.971

9.  In vitro selection of oligonucleotides that bind double-stranded DNA in the presence of triplex-stabilizing agents.

Authors:  Elodie Ayel; Christophe Escudé
Journal:  Nucleic Acids Res       Date:  2009-12-08       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.